Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2007, Article ID 18797, 10 pages
http://dx.doi.org/10.1155/2007/18797
Review Article

The Role of Peroxisome Proliferator-Activated Receptors in Pulmonary Vascular Disease

Department of Medicine, Emory University, Atlanta Veterans Affairs Medical Center, Decatur, GA 30033, USA

Received 1 January 2007; Accepted 30 April 2007

Academic Editor: Jesse Roman

Copyright © 2007 Rachel E. Nisbet et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily that regulate diverse physiological processes ranging from lipogenesis to inflammation. Recent evidence has established potential roles of PPARs in both systemic and pulmonary vascular disease and function. Existing treatment strategies for pulmonary hypertension, the most common manifestation of pulmonary vascular disease, are limited by an incomplete understanding of the underlying disease pathogenesis and lack of efficacy indicating an urgent need for new approaches to treat this disorder. Derangements in pulmonary endothelial-derived mediators and endothelial dysfunction have been shown to play a pivotal role in pulmonary hypertension pathogenesis. Therefore, the following review will focus on selected mediators implicated in pulmonary vascular dysfunction and evidence that PPARs, in particular PPARγ, participate in their regulation and may provide a potential novel therapeutic target for the treatment of pulmonary hypertension.